Evidence that genetics contribute to the risk for prostate cancer stem from genome-wide association studies (GWAS), family-based genetic linkage analyses, and PCa with a family history of other cancers that have inherited mutations in known cancer predisposition genes (e.g., the breast cancer susceptibility genes, BRCA1 and BRCA2). The gene discussed is BRCA2; the disease is posterior cortical atrophy.